Active Motif,
Tools to analyze nuclear function,
Your CartYour Cart 0 items
    
Gene Regulation

TransAM® Transcription Factor Assays

sensitive, quantitative ELISAs for transcription factor activation

TransAM® Kits are sensitive, non-radioactive transcription factor ELISA kits that facilitate the study of transcription factor activation in mammalian tissue and cell extracts. Assays are available for over 40 different targets outlined in the table below. For complete assay details, view the TransAM® Method tab at the bottom of the page.

Why use TransAM over traditional methods?

  • Sensitivity: Up to 100-fold more sensitive than gelshift assays
  • Convenience: Eliminates the use of radioactivity and the need to run gels
  • It's fast: Results can be obtained in less than 5 hours
  • Ease of Analysis: Colorimetric readout enables easy, quantitative analysis with spectrophotometry at 450nm
  • Flexible Format: 96-stripwell format enables both high and low throughput

For a limited time, get 20% Off Your Next TransAM Transcription Factor Assay Kit. Simply reference the code TransAM2017 when you place your order*. See the Terms & Conditions at the bottom of this page. This offer is valid until December 31, 2017.

Our TransAM Assay kits have been cited in more than 1,000 publications.

For more information about individual TransAM kits, or to find out additional information about the publication history of each kit, please click on the target of interest in the table below.

Available Transcription Factor Assays
AP-1 ATF-2
c-Myc C/EBP α/β
CREB & pCREB Elk-1
ER FKHR (FOXO1)
GATA GR
HIF-1 HNF
IRF-3 and IRF-7 MAPK Family
MEF2 MyoD
NF-YA NFATc1
NFκB Nrf2
Oct-4 p53
PPARγ Sp1 and Sp1/Sp3
STAT3 and STAT Family T-bet

 

*TERMS & CONDITIONS: This offer is valid on a single order through December 31, 2017. Offer valid in the United States and Canada and other countries through which Active Motif sells directly. For countries in which Active Motif does not sell directly, please contact your distributor. Offer may not be applied to existing, pending, or prior orders. Cannot be combined with any other promotions or discounts. Limit 1 promotion per order. Promotion code must be referenced when placing your order.

 

The TransAM® transcription factor ELISA advantage

Historically, transcription factor studies have been conducted using gelshift, Western blot and reporter plasmid transfections, which are time-consuming, do not allow for high-throughput and provide only semi-quantitative results. TransAM assays are up to 100 times more sensitive than gelshift techniques, and can be completed in less than 5 hours. Because TransAM is an ELISA-based assay*, there is no radioactivity, and the high-throughput stripwell format enables simultaneous screening of 1-96 samples. Inconsistencies due to variable reporter plasmid transfections are eliminated, along with the need to construct stable cell lines.

How TransAM® transcription factor ELISAs work

The TransAM format is perfect for assaying transcription factor binding to a consensus-binding site. TransAM Kits contain a 96-stripwell plate to which the consensus-binding site oligo has been immobilized. Activated nuclear extract is added to each well and the transcription factor of interest binds specifically to this bound oligonucleotide. A primary antibody specific for an epitope on the bound and active form of the transcription factor is then added followed by subsequent incubation with secondary antibody and Developing Solution to provide an easily quantified, sensitive colorimetric readout (Figure 1).

Flow chart of the TransAM DNA binding transcription factor ELISA method for measurement of activated transcription factors
Figure 1: Flow chart of the TransAM process.

Activated transcription factor in the cell extract binds to the consensus-binding site on the oligo immobilized in the well. Incubation with the supplied primary and secondary antibodies specifically quantifies the amount of activated transcription factor.

* Technology covered under EAT-filed patents and licensed to Active Motif. Use of TransAM in NFκB-related drug discovery may be covered under U.S. Patent No. 6,150,090 and require a license from Ariad Pharmaceuticals (Cambridge, MA, USA).